Parkinson disease (PD) is a devastating neurodegenerative disease without any neuroprotective treatments.
1 Currently, roughly 10 million individuals worldwide have PD, and the number is growing as the population ages. PD exhibits diverse manifestations, including motor and cognitive symptoms.
2,3 Mainstay therapies, such as levodopa and brain stimulation, can improve motor symptoms of PD but do not slow progressive neurodegeneration.
4-6 Despite intensive research, however, potential interventions have not demonstrated consistent neuroprotection.
7-9 Thus, people with PD contend with inexorable and irreversible neurodegeneration and the resulting morbidity and mortality.